Background: Assessment of sleep/wake by electroencephalography (EEG) and
Conclusions:
The WMS on the PiezoSleep narcolepsy screen quantifies the inability to sustain wakefulness and provides an accurate measure of the narcoleptic phenotype in mice.
PiezoSleep offers rapid, scalable assessment of sleep/wake for high-throughput screening in drug discovery.
Keywords
modafinil, mouse, narcolepsy, non-invasive sleep scoring, orexin, piezoelectric, transgenic
Background
Pharmacological studies with arousal state endpoints are typically invasive, resource intensive, and time consuming. Rodent polysomnography requires surgical implantation of electrodes, recovery time, adaptation to sleep implant hardware, and manual scoring of arousal states for the highly accurate detection of sleep microstructure. Using standard electroencephalography (EEG) and electromyography (EMG), wakefulness is defined as low amplitude, desynchronous activity in the EEG across a broad frequency range with variable EMG activity. Sleep in rodents is classified as either rapid-eye-movement (REM) sleep, with pronounced activity in the EEG theta band (4.5-9.5 Hz) and atonia in the EMG, or non-REM (NREM) sleep, with slow, synchronous activity in the EEG delta band (0.5 to 4.5 Hz) and low, steady EMG tone. Some of the burden of rodent polysomnography has been relieved by the development of automated methods of scoring EEG/EMG records. However, the expediency and objectivity value of these methods is diminished for those that require a subset of manually scored samples from individual animals to train the algorithm (1) (2) (3) (4) . Unsupervised, automated scoring algorithms have addressed these limitations of machine learning with varying degrees of accuracy (72-96% agreement) compared to standard manual scoring (5) (6) (7) (8) . Nevertheless, all EEG/EMG based systems of arousal state monitoring are hindered by the time required for surgery, recovery, and in many cases, the repeated-measures experimental designs used for studies in which a small number of animals are used. There is a need in drug discovery for a fully automated method of sleep/wake staging that can scale to a sample size that is amenable to high-powered, between-subject designs for the rapid screening of compounds.
The use of non-invasive proxy-measures of sleep/wake, such as actigraphy, plethysmography, or heartbeat rate correlates of arousal states instead of traditional polysomnography, can expedite sleep/wake determination in rodents (9) (10) (11) (12) (13) (14) . In particular, the use of a highly sensitive motion detector (piezoelectric sensor) on the cage floor to monitor gross motor activity, together with breathing patterns during periods of behavioral quiescence, yields unsupervised sleep/wake detection with 90% accuracy vs. manual EEG scoring (15) . This piezoelectric sleep monitoring system (PiezoSleep) has been used to characterize daily sleep/wake amounts and patterns in a transgenic mouse model of Alzheimer's disease (16) and in 180 knockout lines as part of a large-scale phenotyping program (17) .
Transgenic orexin/ataxin-3 (Atax) mice model the human sleep disorder narcolepsy with high fidelity. Like their human counterparts, Atax mice experience degeneration of wakepromoting orexin (also known as hypocretin) neurons which leads to cataplexy (a sudden, reversible loss of muscle tone and REM-sleep like EEG) and/or increased sleep propensity at times of day when wakefulness would otherwise predominate (18) . Although Atax mice exhibit cataplexy that is readily identifiable according to EEG/EMG-dependent consensus criteria (19) , high inter-individual variability in cataplexy occurrence presents a challenge to sort mice for inclusion in studies with cataplexy reduction as an endpoint (20) . Currently, there is no prescreening method prior to EEG/EMG studies for sorting mice that are highly symptomatic for narcolepsy. In a previous study, Atax mice were monitored with piezoelectric detection of movement and heartrate for a few hours during the light period, but the algorithm for autoscoring was only 73% accurate against manual EEG scoring (14) and missed the time of day in which cataplexy and sleep/wake fragmentation occurs most frequently (20) .
While cataplexy is pathognomonic of narcolepsy, excessive daytime sleepiness (EDS) is the most problematic symptom in patients with narcolepsy (20) . The EDS leads to an inability of patients with narcolepsy to sustain long periods of wakefulness during the Maintenance of Wakefulness Test (MWT) and to fall asleep with short latency on the Multiple Sleep Latency Test (MSLT). Both tests are indicators of symptom severity; the MSLT is used in the diagnosis of narcolepsy and the MWT is used to assess treatment efficacy (21) . Modafinil (MOD) is a firstline choice of treatment for EDS in patients and promotes EEG/EMG-defined wakefulness in narcoleptic mice but is ineffective in cataplexy reduction (21, 22) . Although neural mechanisms (23) and response to treatment (24, 25) may differ between cataplexy and sleep/wake fragmentation, a link between these symptoms is suggested by the finding that patients with severe cataplexy are the least able to stay awake on the MWT (26) . Drug discovery efforts aimed at finding improved therapeutics for narcolepsy would benefit from a translational assay in mice similar to the MSLT and MWT that is rapid, scalable, and not dependent upon polysomnography nor sleep deprivation protocols (27) .
In the current report, we demonstrated the proof of principle that the PiezoSleep system can be applied to address two problems in the preclinical development of wake-promoting therapeutics for narcolepsy. First, we addressed the need for a non-EEG/EMG based translational test of sleepiness severity that can be used for subject stratification by introducing the wake-maintenance score (WMS)-a measure of sleep/wake fragmentation determined by the PiezoSleep narcolepsy screen. The subset of Atax mice that were identified with the lowest WMS were subjected to follow-up polysomnography to quantify cataplexy. Second, we conducted a dose-response study with MOD to demonstrate that PiezoSleep can fill the need for a non-invasive, rapid means to quantify sleep time and consolidation at a scale amenable to screening wake-promoting therapeutics in drug discovery.
Methods
All experimental procedures were approved by the Institutional Animal Care and Use Committee at Reset Therapeutics and were conducted in accordance with the principles set forth in the Guide for Care and Use of Laboratory Animals of the National Institute of Health.
Animals
Male and female hemizygous transgenic B6.Cg-Tg(HCRT-MJD)1Stak/J mice (Atax) and wild type (WT) littermates (JAX stock #023418, Jackson Labs, Bar Harbor, ME) were used (18) .
Separate cohorts were used for immunohistochemistry, development of the narcolepsy phenotyping assay and PiezoSleep narcolepsy screen, calculation of the receiver operator characteristic (ROC) curve for the WMS, EEG/EMG and video monitoring, and pharmacology.
Male C57BL/6J mice (JAX stock #000664, Jackson Labs, Bar Harbor, ME) were also used in pharmacological studies. Male CD-1 mice (Charles River Laboratories, Hollister, CA), 7-8 weeks old, were used in pharmacokinetic studies. Animals were individually housed, except for CD-1 mice which were housed 3 per cage, at 22-25 o C, 30-70% relative humidity, and LD12:12 with ad libitum access to food, water and nesting material.
Immunohistochemistry
All histological procedures and cell counts were performed at Jackson Laboratories (Bar Harbor, ME). ) and was connected to a single channel tube amplifier (RoMo version 1.2, Signal Solutions, Lexington, KY). Each amplifier fed into a digital acquisition device connected to a computer for data collection and sleep/wake determination as previously described (9, 15, 28) . Briefly, signals were amplified and filtered between 0.5 and 10 Hz and analog-to-digital converted at 120 Hz sampling rate. The frequency, amplitude, and peak spectral energy of the signal were evaluated in 2 second increments over a tapered, 8 second window to automatically calculate a sleep/wake decision statistic by simple linear discriminant analysis. Signals were classified as sleep if they exhibited a periodicity with a consistent, low relative amplitude at a frequency in the typical breathing range (1-4 Hz).
Wakefulness was associated with high amplitude signals with variable frequency and broad spectral energy. Signal features related to these properties were extracted and combined to obtain a decision statistic for each interval. Over time, the decision statistics per increment accumulated in a bimodal distribution. The saddle point of the distribution was determined using an adaptive threshold for the classification of sleep and wake. Bouts of contiguous intervals of sleep or wake were defined to terminate when an interval, equal to the minimum bout length of (20), sleep and wake data from ZT12-18 were used to differentiate mice based on their ability to maintain long WBD at that time of day. Scatterplots of time spent in short SBD (< 8 min) vs. long WBD (≥ 32 min) were used to screen Atax mice that were highly symptomatic for murine narcolepsy (i.e., compared with other Atax mice, they spent more than the mean amount of time in short SBD and less than the mean amount of time in long WBD.) All mice were assigned a WMS based on their ratio of time in long WBD:short SBD during ZT12-18 for the PiezoSleep narcolepsy screen. The optimal threshold for the WMS to detect a narcoleptic phenotype with high sensitivity and specificity was determined by a ROC curve in which the WMS cutoff was adjusted from 0.25-50 on data from all available cohorts (N = cohorts) of genotyped Atax (N = 148) and wild-type colony mates (N = 36).
EEG/EMG & video monitoring
A separate cohort of male Atax mice (N = 37, aged 11.6 weeks, 26.6 ± 0.4 g) was subjected to the PiezoSleep narcolepsy screen to identify the individuals that were the most highly symptomatic for narcolepsy and thus the best candidates for EEG and EMG studies. The 16 Atax mice with the lowest WMS were surgically implanted at 16.9 ± 0.2 weeks of age (30.2 ± 0.7 g) with transmitters (F20-EET, Data Sciences International, St. Paul, MN) for EEG and EMG recording as previously described (29) . Mice were anesthetized with isoflurane and transmitters were placed IP along the midline. Biopotential leads were routed subcutaneously to the head, and EMG leads were positioned bilaterally through the nuchal muscles. Cranial holes were drilled 1 mm anterior to bregma and 1 mm lateral to midline, and contralaterally, 2 mm posterior to bregma and 2 mm lateral to midline. EEG leads were placed subchranially over the dura and attached to the skull with cyanoacrylate and dental acrylic. Analgesia was managed with prophylactic ketoprofen (5 mg/kg, SC) followed by buprenorphine (0.1 mg/kg, SC) upon emergence from anesthesia. Ketoprofen (5 mg/kg, SC, QD) was continued for 3 days 
Compound formulation

Modafinil (MOD, 2-[(diphenylmethyl)sulfinyl]acetamide) was purchased from Focus
Synthesis (San Diego, CA) for dosing in CD-1 and WT and from Advanced ChemBlocks, Inc.
(Burlingame, CA) for dosing in Atax mice because MOD was no longer available from Focus Synthesis. For pharmacokinetic studies, MOD was formulated in 1.25% Hydroxypropyl Methylcellulose / 0.25% Methylcellulose in Water for Injection, which formed a homogenous suspension. For efficacy studies, after MOD was weighed, premade vehicle (20% propylene glycol, 25% polyethylene glycol 400 in water for injection) was added at a volume appropriate for the highest concentration, followed by overnight sonication, which produced a clear solution.
Serial dilutions were created and re-sonicated approximately 6 h prior to dosing. All dosing solutions were formulated within 24 h prior to dosing.
Pharmacokinetic studies
Male CD-1 mice were acclimated for a minimum of 3 days prior to drug administration. 
Efficacy studies
In a between-subjects design, male C57BL/6 mice (WT, 15.7 ± 0.1 weeks, 28.5 ± 0.2 g, N = 12/group) and Atax mice (16.4 ± 0.7 weeks, 30.0 ± 0.7 g, N = 9-10/group) were dosed separately in two pharmacological studies. A between-subjects design was chosen to ensure mice were drug naïve at the time of dosing. Mice were loaded into PiezoSleep cages for 42 h acclimation, followed by 29 h baseline recording prior to dosing at ZT5 (14:00), the time of day in which wake-promoting/sleep-inhibiting effects would be expected to be most pronounced because baseline sleep is typically high then. Syringes were filled immediately prior to dosing, which was completed within a 15-minute window. After pharmacokinetic studies (Table 1 ) and based on efficacy in previous reports (22, 30) , mice received either MOD (10, 30, 50, 100 mg/kg, 10 mL/kg) or vehicle orally and were recorded for 44 h post dosing. Mice were undisturbed during the recording period except for dosing. Groups were balanced across dosing order, dosing personnel, and cage location per shelf and rack. Atax mice had previously been screened in the narcolepsy phenotype assay, and highly symptomatic mice were balanced across dosing groups. 
Data analysis and statistics
Statistics were performed using GraphPad Prism version 7.03 (La Jolla, CA). Unless otherwise noted, all data are presented as the mean ± S.E.M. Orexin cell counts were compared between male and female Atax and WT mice using two-way analysis of variance (ANOVA). In phenotyping studies, sleep time and mean SBD and WBD were compared between Atax and WT mice using two-way mixed-model ANOVA on factors "genotype" (between subjects) and "hour" (within subjects). Histograms representing the distribution of time spent in various SBD and WBD were evaluated using two-way mixed-model ANOVA on factors "genotype" (between subjects) and "bout duration bin" (within subjects). Pearson correlations were used to evaluate the day-to-day variability in individual mice for measures of sleep/wake fragmentation. Wake-maintenance scores were compared between genotypes using two-tailed, unpaired t test. For evaluation of the WMS to accurately predict a narcoleptic phenotype using a vs. EEG/EMG with video recording over 24 h were made within subjects using two-way repeated-measures (RM) ANOVA, and for 24 h totals using two-tailed, paired t test.
Pharmacological data were assessed within genotypes by two-way mixed-model ANOVA on between-subjects factor "drug condition" and within-subjects factor "hour" or "bout duration bin."
The maximum sleep deficit was calculated as the minimal value in the cumulative change from baseline in sleep % time during the 12 h post dosing. Consolidation of wakefulness after dosing was measured as the change from baseline in the % time spent in long wake bouts ≥ 8 min.
Sleep deficits and consolidated wakefulness were compared between genotypes after dosing using two-way ANOVA. For each analysis, when ANOVA indicated significance (α = 0.05), contrasts between relevant factor levels (vs. WT or vehicle, as appropriate) were detected post hoc with Bonferroni's multiple comparisons test. The total sample size (N = 97) for the pharmacological study permitted sufficient power (0.8) for the detection of an effect size of 36%
at P < 0.05 (computed using WebPower https://webpower.psychstat.org/wiki/).
Results
Histology
To confirm orexin cell loss from Atax mice taken out of cryopreservation at JAX, orexin cell counts were compared between the transgenics and their WT littermates at an adult age in which they would be used for sleep studies. Representative images (Figure 1 ) of the tuberal region of the hypothalamus and cell counts (Table 2) 
Phenotyping of narcolepsy model
Piezoelectric monitoring of sleep/wake was used to evaluate the phenotype of Atax mice , and wake-maintenance scores (ratio of time in long wake bouts to short sleep bouts) (C). Wake-maintenance scores were rescaled without outliers for clarity (D).
The accuracy of the WMS to detect a narcoleptic phenotype was evaluated using a ROC curve in which the threshold for defining the narcoleptic phenotype was adjusted from 0.25 to 50 on data from mice genotyped as either Atax or WT (Figure 4) . Based on the ROC curve, the optimal cutoff for the WMS was 3.25 to detect murine narcolepsy with 89% sensitivity (95% CI Figure 6D ). After MOD (10-100 mg/kg), the percentage of time spent in these long sleep bouts was reduced in dose-related manner, F(28, 385) = 5.38, P < 0.0001, and the distribution of time spent in the different SBD bins shifted such that more time was spent in shorter bouts than longer bouts (i.e., leftward shift of the peak), especially at the highest dose. Unlike WT mice, Atax mice in baseline and vehicle conditions NREM (B, black line), REM (B, gray dashed line), cataplexy (C, black line) , and wheel running (C, gray dashed line) as measured by manual scoring of EEG/EMG/video recordings. Two-way repeated-measures analysis of variance with Bonferroni's multiple comparisons: * P < 0.05 vs. EEG/EMG/video. 
Discussion
Piezoelectric monitoring of sleep/wake was used to identify key features of the narcoleptic phenotype that distinguish Atax mice by sleepiness severity, thus enabling rapid, non-invasive sorting of mice for further evaluation with EEG/EMG. The PiezoSleep narcolepsy screen was used to assign a WMS-the ratio of time spent in long WBD (≥ 32 min) to time in short SBD (˂ 8 min) during the first half of the dark period-to individual mice. The WMS with a cutoff value of 3.25 accurately differentiated genotype-confirmed Atax mice from WT controls.
The WMS spanned a 15-fold difference between the most severely narcoleptic mice and their WT littermates. The PiezoSleep system was also demonstrated to detect changes in sleep/wake time and consolidation after administration of the wake-promoting therapeutic modafinil in normal and transgenic mice. Using this method, the efficacy of wake-promoting compounds can be determined in a 5-arm study with up to 60 mice in less than one week for high-throughput screening in vivo.
The PiezoSleep narcolepsy screen was designed to be a translational test of the ability to sustain long periods of wakefulness as is assessed in humans by the MWT and the MSLT. (27) . The PiezoSleep narcolepsy screen provides a rapid, automated alternative to the murine MSLT and does not require the manipulation of sleep homeostatic processes to obtain the measurements. The 89% sensitivity and 92% specificity of the WMS on the PiezoSleep narcolepsy screen for mice is reasonably comparable to that of sleep latency on the MSLT (95% sensitivity and 73% specificity) and MWT (84% sensitivity and 98% specificity) for humans (31) . The translational utility of the PiezoSleep phenotyping assay is limited by the (9, 15) . The current analysis in Atax mice does not permit this level of scrutiny, as the PiezoSleep and EEG recordings were staged in 2 and 10 second epochs, respectively, and occurred 8 weeks apart in different environments (e.g., the EEG recordings occurred in standard cages equipped with running wheels in a sound-attenuated recording chamber).
Wakefulness over 24 h was 3.6% higher after piezoelectric monitoring than after EEG/EMG recording in the current study, vs. 2.3% lower as previously reported (15) . In addition to the caveats between methods as noted above, the discrepancy could be due to the different mouse strains studied (Atax vs. CFW Swiss Webster). It is unlikely that the breathing patterns of Atax mice would cause the PiezoSleep assay to misconstrue sleep as quiet wakefulness, and thus overinflate the measurement of time awake compared to EEG/EMG in the current study.
Piezoelectric monitoring did not detect more wakefulness in Atax mice than in WT (Figure 2A In the current study, piezoelectric measurement of sleep/wake was evaluated as a method to screen wake-promoting compounds rapidly and at scale for the development of therapeutics for narcolepsy. Dosing WT mice at ZT5 was chosen as the first pass of screening using MOD because of the similarities between Atax and WT mice in the high amount of sleep per hour (Figure 2A ) and in the very short WBD ( Figure 2C ) during the light period. Modafinil (50 mg/kg) with total brain exposure of 33.7 μM approximated the ED50 in both WT and Atax mice in terms of the time course of sleep inhibition, the maximum sleep deficit induced, and the consolidation of wakefulness ( Figure 6 ) and is recommended as the positive control for screening the wake-promoting efficacy of compounds. Using the PiezoSleep assay, a total of 106 mice in two cohorts were screened across 4 concentrations of MOD vs. vehicle in two weeks, representing substantial improvement in efficiency over conventional sleep/wake bioassays (22, 30) . Future studies are needed to validate the PiezoSleep assay for pharmacological studies at different times of day and with hypnotics. Of particular interest would be to test the hypothesis that wake-promoting therapeutics administered at ZT12 would rescue the narcoleptic phenotype of Atax mice as measured by the WMS on the PiezoSleep narcolepsy screen.
Piezoelectric monitoring of sleep/wake offers advantages over video-based methods, even those that claim to discriminate NREM and REM sleep (35) for several reasons. Because PiezoSleep does not depend on a visual signal, it permits mice to sleep while burrowed in nesting material for assessment of more ecologically relevant behavior. The highly sensitive piezoelectric sensor captures a detailed respiratory measure that enables it to distinguish quiet, resting wakefulness from sleep using relevant physiology (15) . To the best of our knowledge, sleep state discrimination based on postural changes in the aspect ratio of the body on video recordings (35) has not been replicated nor validated in mouse models that have been reported to feature obesity, such as Atax mice (18, 36) .
Conclusions
The non-invasive, unsupervised piezoelectric monitoring of sleep/wake is a new tool for efficacy studies with arousal state endpoints and can be used to solve two problems in the preclinical development of wake-promoting therapeutics for narcolepsy. First, the PiezoSleep narcolepsy screen can be used to determine a WMS that quantifies sleepiness severity and can be used to improve phenotypic sorting for resource intensive EEG/EMG studies. Second, PiezoSleep can be used to rapidly quantify sleep/wake time and consolidation for highthroughput screening in vivo for drug discovery. 
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